Free tools Windows power users keep installed
One-click scans. No signup required.
The three stocks named in the rate-resilience thesis are Eli Lilly (LLY), Medtronic (MDT) and Johnson & Johnson (JNJ). Their healthcare businesses may be less exposed to changes in consumer spending than many discretionary companies, but none is guaranteed to rise—or to outperform—whether rates go up or down. The investment case depends on each company’s business, execution, valuation and financial position, not just the Federal Reserve’s next decision.
What the market was expecting from the Fed
In coverage published October 2, 2026, traders had reduced their bets on an October rate hike after a cooler-than-expected September employment report. The decision remained uncertain and dependent on incoming data, according to the market report. That is a dated snapshot, not a prediction of the eventual decision or a guide to current rate expectations.
Interest rates can affect stocks through more than one channel. Higher rates can weigh on valuations, while some financial companies may benefit from higher rates, as Goldman Sachs notes. That broad sector observation does not establish how these three healthcare stocks will perform. Healthcare demand may be relatively less discretionary, but the companies’ share prices remain exposed to valuation changes, financing conditions and company-specific results.
Why these three stocks were presented as resilient
The October 3, 2026 Motley Fool article’s shared argument is that healthcare demand may be less directly tied to interest-rate-driven changes in discretionary spending. The reasons it gives for each stock are distinct:
#1 Best Overall
| Company | Business exposure | Article’s cited driver | Important qualification |
|---|---|---|---|
| Eli Lilly (LLY) | Pharmaceuticals | GLP-1 medicines and reported pipeline diversification | The article says GLP-1 medicines represent nearly 66% of revenue; that figure was not independently verified against company filings. |
| Medtronic (MDT) | Medical devices | Product investment and a turnaround, including the Hugo surgical robot | Its reported growth rates, dividend streak and yield are article-reported, not independently verified here. |
| Johnson & Johnson (JNJ) | Pharmaceuticals and medical devices | Business breadth and a long dividend-raising history | The dividend history and yield cited by the article were not independently checked; yield changes with share price. |
Eli Lilly: growth opportunity and concentration risk
The article identifies Lilly as a leading maker of GLP-1 weight-loss medicines and attributes nearly 66% of company revenue to those medicines. It also says Lilly used cash generation to diversify its pipeline, citing 2026 acquisitions in autoimmune and allergic disease, mental health, and infectious disease. Those concentration and transaction details are the article’s claims, not independently verified current figures or transaction records.
The case therefore has two sides: the cited GLP-1 business is a growth driver, while its reported revenue share makes business performance meaningfully tied to that product category. Pipeline diversification could broaden future sources of growth, but acquisitions and research programs do not guarantee successful products or offset changes in the core business. Before relying on these claims, check Lilly’s current filings and releases for revenue mix, deal status and development updates.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Medtronic: product-led recovery, with figures to verify
The article frames Medtronic as simplifying its business and investing in products, including the Hugo surgical robot. It reports 8.4% sales growth in fiscal 2026 and nearly 14% sales growth in the first quarter of fiscal 2027. Both are figures attributed to The Motley Fool in 2026; the underlying company earnings materials were not independently verified.
If the reported growth reflects durable demand and successful product execution, it would support the turnaround case. But a growth rate for one fiscal period does not establish a long-term trend, and product investment carries execution risk. The article also reports 49 consecutive years of dividend increases and a 3.3% yield at publication. The streak is article-reported, while the yield is a time-sensitive ratio that changes with the share price; neither should be treated as a current confirmed metric without checking Medtronic’s disclosures and market price.
Johnson & Johnson: breadth and dividend history
The article describes J&J as spanning pharmaceuticals and medical devices, a mix that gives it more than one business area. It says the company had raised its dividend annually for more than six decades and reports a 2% yield at publication. These are article-reported details rather than independently verified current metrics. The yield can move as the share price changes, and business breadth by itself does not establish that earnings or the stock will be steady through every rate environment.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What “win either way” does—and does not—mean
“Win either way” is best read as a thesis about possible resilience, not a promise of positive returns under both rising and falling rates. Rate changes can affect valuations and financing conditions, and healthcare companies still face their own operating risks. The article supplies a narrative comparison, not enough current primary-source evidence to rank the three by valuation, balance-sheet sensitivity or expected total return.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Rank #4
- Compare current valuation and company guidance rather than assuming defensive demand makes a stock inexpensive.
- Check product, pipeline and sales claims against each company’s latest filings or earnings releases.
- Evaluate dividend sustainability from current company disclosures; a long record or a past yield alone does not establish future income or returns.
- Consider your time horizon and diversification. A single stock can fall even when its industry is relatively resilient.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
